Las Vegas, NVNCT07015697Now EnrollingIRB Ready

Recurrent or Metastatic Solid Tumors Clinical Trial in Las Vegas, NV

Access cutting-edge recurrent or metastatic solid tumors treatment through this clinical trial at a research site in Las Vegas. Study-provided care at no cost to qualified participants.

Sponsored by Daiichi Sankyo

Quick Self-Assessment

See if you qualify for this Las Vegas location

Preparing your pre-screening questions…

Expert Care in Las Vegas

Access recurrent or metastatic solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related recurrent or metastatic solid tumors treatment provided free

Apply for This Las Vegas Location

Check if you qualify for this recurrent or metastatic solid tumors clinical trial in Las Vegas, NV

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Las Vegas

    Convenient for NV residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Las Vegas site if eligible
  4. 4Begin participation

About This Recurrent or Metastatic Solid Tumors Study in Las Vegas

This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metastatic solid tumors.

Sponsor: Daiichi Sankyo

Who Can Participate

Inclusion Criteria

Adults ≥18 years or the minimum legal adult age (whichever is greater).
a) Disease State: If HER2 status is required for eligibility (for all populations), a documented HER2 test result must be available. Breast Cancer: adults with pathologically documented unresectable or metastatic breast cancer HER2-positive BC: have received a prior anti-HER2-based regimen. For HER2-positive BC participants in Part 2 only, prior anti-HER2 based therapy should have been received in either:
the metastatic setting, or
the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. HR-, HER2-low BC: have received a prior systemic cytotoxic therapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing (neo)adjuvant chemotherapy. HR+, HER2-low/ultralow BC: have received previous ET AND an additional line of ET must not be the next line of treatment considered in the participant's best interest.
For participants in Part 2 with HR+ HER-2low/ultralow BC, the following criteria also apply:
had disease progression while receiving 1 previous line of ET with a CDK4/6i and is not expected to benefit from immediate use of a second line of ET, OR
had disease progression on at least 2 previous lines of ET with or without a target therapy such as CDK4/6, mTOR or PI3-K inhibitors) administered for the treatment of metastatic disease
participants may not have received more than 2 prior lines of cytotoxic therapy in the recurrent or metastatic setting. NSCLC, HER2 mut: adults with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. b) Part 2 only: At least 1 RECIST 1.1 measurable lesion on CT or MRI.
Radiologic or objective evidence of disease progression on or after the last systemic therapy prior to starting trial intervention. Key

Exclusion Criteria

1\. Prior treatment with ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor; 4. Medical history of MI within 6 months before enrollment or symptomatic CHF (New York Heart Association class II to IV). Participants with troponin levels above ULN at screening (as defined by the manufacturer), and without any MI-related symptoms should have a cardiologic consultation during the Screening Period to rule out MI. 5\. Has a corrected QT interval (QTcF) prolongation to \> 480 ms (regardless of participant's sex) based on average of the screening triplicate 12-lead ECG. 6. Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Las Vegas?

Yes, this clinical trial (NCT07015697) has an active research site in Las Vegas, NV that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent or Metastatic Solid Tumors Treatment Options in Las Vegas, NV

If you're searching for recurrent or metastatic solid tumors treatment options in Las Vegas, NV, this clinical trial (NCT07015697) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Las Vegas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced recurrent or metastatic solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent or metastatic solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Las Vegas, NV

See all advanced solid tumors clinical trials recruiting in Las Vegas — not just this study.

Browse Advanced Solid Tumors Trials in Las Vegas →

Browse More Trials by Condition

Advanced Solid Tumors TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Las Vegas?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Las Vegas, NV